EMLA PATCH 2.5 % — DIN 02057794
PRILOCAINE : 2.5 % LIDOCAINE : 2.5 % · ASPEN PHARMACARE CANADA INC. · PATCH · wholesale supply in Canada
Health Canada status: MARKETED
What is EMLA PATCH?
EMLA PATCH 2.5 % contains PRILOCAINE : 2.5 % LIDOCAINE : 2.5 %. It is listed in the Health Canada Drug Product Database under DIN 02057794, held by ASPEN PHARMACARE CANADA INC., supplied as PATCH for TOPICAL administration. Health Canada currently lists it as marketed, status dated 08-May-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Is there a generic Prilocaine, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Prilocaine, Combinations, across 5 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ASPEN PHARMACARE CANADA INC. | 2 | 2 | EMLA CREAM, EMLA PATCH | Sourceable in Canada |
| DENTSPLY CANADA LIMITED | 2 | 1 | 4% CITANEST FORTE DENTAL WITH EPINEPHRINE 1:200,000, DENTSPLY 4% PRILOCAINE AND EPINEPHRINE INJECTION 1:200,000 | Sourceable in Canada |
| NOVOCOL PHARMACEUTICAL OF CANADA INC | 1 | 1 | PRILOCAINE HCL 4% EPINEPH 1:200000INJ | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2.5 % |
|---|---|
| Dosage form | PATCH |
| Route | TOPICAL |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Prilocaine, Combinations |
|---|---|
| ATC code | N01BB54 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02057794 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2057794 |
| Brand name | EMLA PATCH |
| Generic / active ingredient | PRILOCAINE : 2.5 % LIDOCAINE : 2.5 % |
| Market authorization holder | ASPEN PHARMACARE CANADA INC. |
| Health Canada schedule | Ethical |
| ATC code | N01BB54 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N01BB |
| Current status | MARKETED |
| Status date | 08-May-2018 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 5 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| 4% CITANEST FORTE DENTAL WITH EPINEPHRINE 1:200,000 | 0.005 MG | SOLUTION | DENTSPLY CANADA LIMITED | MARKETED | 02347695 |
| EMLA CREAM | 2.5 % | CREAM | ASPEN PHARMACARE CANADA INC. | MARKETED | 00886858 |
| PRILOCAINE HCL 4% EPINEPH 1:200000INJ | 40 MG | SOLUTION | NOVOCOL PHARMACEUTICAL OF CANADA INC | MARKETED | 00393746 |
| DENTSPLY 4% PRILOCAINE AND EPINEPHRINE INJECTION 1:200,000 | 5 MCG | SOLUTION | DENTSPLY CANADA LIMITED | CANCELLED POST MARKET | 00519227 |
2 · Same class — other molecules in ATC N01BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lidocaine | AMNIOCENTESIS TRAY 1% · ANTECUBITAL CENT VENOUS CATHETERIZATION KIT · ARTHROGRAM TRAY 1% · ATELOCOLLAGEN IMPLANT · +39 more | 72 | 26 | Yes |
| Lidocaine, Combinations | 2% LIDOCAINE AND EPINEPHRINE 1:100,000 INJECTION USP · 5% XYLOCAINE MPF WITH GLUCOSE 7.5% INJECTION · ARROW CENTRAL VENOUS CATHETERIZATION KIT · ARROW MULTI-LUMEN CENTRAL VENOUS CATHETER KIT · +55 more | 72 | 16 | Yes |
| Articaine, Combinations | 4% ASTRACAINE DENTAL WITH EPINEPHRINE 1:200,000 (0.005MG/ML) · 4% ASTRACAINE DENTAL WITH EPINEPHRINE FORTE 1:100,000 (0.01MG/ML) · ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE INJECTION · ORABLOC 1:100,000 · +10 more | 18 | 12 | Yes |
| Bupivacaine | BUPIVACAINE HEAVY INJECTION BP · BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP · BUPIVACAINE HYDROCHLORIDE INJECTION USP · BUPIVACAINE HYDROCHLORIDE INJECTION USP .25% · +12 more | 42 | 10 | Yes |
| Mepivacaine | 3% POLOCAINE DENTAL · CARBOCAINE 1% · CARBOCAINE 2% · CARBOCAINE 3% · +7 more | 15 | 7 | Yes |
| Ropivacaine | NAROPIN · NAROPIN INJ 7.5MG/ML · ROPIVACAINE HYDROCHLORIDE INJECTION · ROPIVACAINE HYDROCHLORIDE INJECTION USP · +2 more | 13 | 6 | Yes |
| Bupivacaine, Combinations | BUPIVACAINE HCL 0.5% AND EPINEPHRINE 1:200,000 INJECTION · MARCAINE · MARCAINE 0.5% AND EPINEPHRINE 1:200,000 LIQ · MARCAINE E · +5 more | 12 | 5 | Yes |
| Prilocaine, Combinations | 4% CITANEST FORTE DENTAL WITH EPINEPHRINE 1:200,000 · DENTSPLY 4% PRILOCAINE AND EPINEPHRINE INJECTION 1:200,000 · EMLA CREAM · EMLA PATCH · +1 more | 5 | 4 | Yes |
| Combinations | CETACAINE LIQUID · ORAQIX | 2 | 2 | Yes |
| Prilocaine | 4% CITANEST PLAIN DENTAL · DENTSPLY 4% PRILOCAINE HYDROCHLORIDE DENTAL INJECTION | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N01BA | Benzocaine · Chloroprocaine · Combinations,Of Anesthetics · Procaine · Tetracaine | 13 | 1 |
| N01BX | Phenol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.